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ABSTRACT 
Purpose: Myoblasts are capable of forming muscle fibers after transplantation and are 
therefore envisioned as a treatment for urinary incontinence after radical 
prostatectomy. However, the safety of this treatment and the interaction of myoblasts 
with remaining neighboring cancer are unknown. We investigated the interactions 
between myoblasts and prostate carcinoma cells in vitro and in vivo. 
Materials and Methods Myoblasts isolated from rectus abdominis were used in a 
series of co-culture experiments with prostate cancer cells and subcutaneously co-
injected in vivo. Cell proliferation, cell cycle arrest and apoptosis of cancers in co-
culture with myoblasts were assessed. Tumor volume and metastasis formation were 
evaluated in a mouse model. Tissue specific markers were assessed by 
immunohistochemistry, FACS analyses, Western blot and RT-qPCR.  
Results: In this study we have demonstrated that myoblasts, in proximity to tumor, 
provide paracrine TNFα to their microenvironment, decreasing tumor growth of all 
prostate cancer cell lines examined. Co-culture experiments showed induction of cell 
cycle arrest, tumor death by apoptosis and increased differentiation of myoblasts. This 
effect was largely blocked by TNFα inhibition. The same outcome was demonstrated in 
a mouse model, where co-injected human myoblasts also inhibited tumor growth and 
metastasis formation of all prostate cancer cell lines evaluated.  
Conclusions: Myoblasts restrict prostate cancer growth and limit metastasis 
formation by paracrine TNFα secretion in vitro and in vivo. 
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INTRODUCTION 
Skeletal muscle comprises nearly 50% of the human body, is richly vascularized but 
rarely the site of cancer metastases. The cellular and molecular mechanisms 
underlying this phenomenon are not yet understood 1. An intrinsic protective 
mechanism avoiding ingrowth of metastatic cells and formation of new tumors seems 
to exist. At the same time, skeletal muscles are the source of myoblasts 2, which are 
capable of regenerating muscle fibers, and therefore are investigated for the 
treatment of several muscular dysfunctions, including stress urinary incontinence 
(SUI) 3, a common complication after radical prostatectomy 4. Preclinical studies have 
demonstrated that myoblasts, when implanted in the urinary sphincter, efficiently 
restore continence 5. The pelvic floor is also a frequent site of residual prostate 
cancer cells 6, but until now no investigations targeted cell fate and possible 
interactions between myoblasts and vicinal preexisting cancer. 
Parallels have long been drawn between stem cells and cancer cells. In fact, both cell 
types share common features such as capacity for self-renewal, differentiation 
potential, relative quiescence, resistance to drugs and toxins, resistance to 
apoptosis, secretion of growth factors and stimulation of angiogenesis by production 
of vascular endothelial growth factor (VEGF) 7. These features could result in two 
possible outcomes: Cell proliferation or cell death. For instance, the presence of 
VEGF, which is secreted by many stem cells and progenitor cells including myoblasts 
8, has the potential to promote prostate cancer angiogenesis leading to enhanced 
tumor growth and bone metastasis 9. On the other hand, myoblasts are activated by 
inflammation and use inflammatory cytokines to perform and regulate their cross-talk 
for activation and differentiation 2. These same inflammatory cues, paracrine 
secreted by myoblasts, could trigger cancer apoptosis. 
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A recent study successfully demonstrated inhibition of melanoma cell growth in the 
presence of myoblasts, but failed to describe a possible intercellular mechanism that 
explains this cell behavior 10. Upon differentiation, myoblasts secrete tumor necrosis 
factor alpha (TNFα), which plays a key role in myoblast activation and differentiation, 
thereby linking inflammation to muscle regeneration 11. In tumor cells, TNFα activates 
two parallel pathways, nuclear-factor-κB (NF-κB) or c-Jun N-terminal kinase (JNK). If 
NF-κB is activated, TNFα acts as a growth promoter, stimulating proliferation and 
metastasis. However, if JNK is turned on, a Caspase3-dependent-apoptosis-pathway 
leads to cell death 12. In this study, we demonstrate that myoblast-secreted-TNFα is 
capable of influencing vicinal prostate carcinoma by inducing cell cycle arrest and 
apoptosis in vitro and in vivo. Additionally, despite the proximity to prostate cancer, 
myoblasts will rapidly differentiate into well-organized myotubes. Cell-therapy with 
myoblasts might provide an ideal treatment of post-prostatectomy urinary 
incontinence by improving sphincter function and inhibiting potential recurrent 
prostate cancer growth in the pelvic floor. 
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MATERIAL AND METHODS 
 
Cell Isolation and Culture 
Upon ethical-approval and informed-consent, myoblasts were isolated from rectus 
abdominis biopsies of four male patients (65 ± 6.4y) undergoing abdominal surgery. 
Biopsies were immediately processed according to established protocols 13 and cells 
were expanded until passage 2 (P2) with a medium change every third day. Cell 
characterization was performed by FACS, Immunocytochemistry, RT-qPCR and 
Western Blot. Muscle tissue formation was assessed by injecting 5 million myoblasts 
with a collagen carrier (Collagen-type-I Rat tail,BD) into the subcutaneous space of 
nude-mice. Tissues were retrieved after three and six weeks for histological analysis. 
The three prostate carcinoma cell lines (ATCC-LGC Standard) were chosen 
according to their increasing clinical aggressiveness. They are retrieved from lymph 
node (LNCaP), bone (PC3), and brain (DU145) metastases. An aggressive vulvar 
leiomyosarcoma cell line (SK-LMS1) served as an additional cancer control. An 
indirect co-culture model (BD Falcon™) was applied, where cells shared culture 
medium (DMEM enriched with 10% fetal bovine serum (FBS) and 1% 
streptomycin/penicillin) thereby exchanging their cellular products without direct cell-
cell-contact. Cancer cells were co-cultured with myoblasts of each patient for 10 
days and analyses were performed at days 1, 4, 7 and 10. Myoblasts alone and 
cancer cell line cultures were used as control. To maintain the total number of 
seeded cells in the single cell controls (myoblast or cancer alone), we have 
placed cells in both compartments, the culture dish and the insert. All 
experiments were performed in triplicates and medium change was done every third 
day. TNFα was neutralized with a mouse monoclonal anti-TNFα antibody (Sigma,T-
6817). 
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Growth Rate and Fiber Formation Assay (FFA)  
In all cases, triplicate samples of log phase cells were plated at a density of 
5x103cells/cm2. Cell number and viability was confirmed after trypsinisation by 
toluidine blue staining (n=36). The formation of myofibers was examined on slide 
chambers and, after 8 days in differentiating condition myofibers were fixed 
(methanol, 7min), stained (1:20 Giemsa, 1h) and air dried. Images were taken with a 
Leica-Imager-M1 Microscope. Five high‐power‐fields (HPF) per sample were 
analyzed (n=30) and results were expressed as differentiation rate, which was 
calculated by the number of nuclei in differentiated myofibers/HPF divided 
by the total number of nuclei/HPF. 
 
Western Blot 
Cells were washed with PBS/protease inhibitor (Sigma) and lysed with lysis buffer 
(50mM Tris-HCl, 150mM NaCl, 10% glycerol, 1% Triton X-100, 2mM EDTA, 40mM ß-
glycerophosphate, 50mM sodium-fluoride, 10µg/ml leupeptin, 10µg/ml aprotinin, 1µM 
pepstatinA, 1mM PMSF). Samples were centrifuged (10min, 13000rpm), and proteins 
determined in the supernatant. Culture medium proteins were concentrated by 
filtering through a 10kDa filter (Amicon Ultra, Millipore). Total protein was measured 
using DC™ Protein-Assay (Bio-Rad), and 30 µg of protein lysate was loaded on 12% 
Biorad gels. Proteins were transferred onto PVDF-membranes (Millipore), blocked 
(1h, 5% non-fat-dry-milk), and incubated (4°C, overnight) with anti-Desmin (1:100,BD 
Biosciences), anti-MyH (1:6,DSHB), anti-TNFα (1:500,Sigma), anti-p21WAF1 
(1:1000,Calbiochem), Cleaved Caspase-3-Asp175 (1:1000,Cell- Signaling) and anti-
GAPDH (1:2000,Sigma). Membranes were washed, incubated with HRP-conjugated 
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secondary antibody and developed by ECL-technique (ECL-Kit,Amersham). 
 
RT-qPCR 
RNA extraction, cDNA preparation and RT-qPCR reactions were done using 
Taqman® gene expression assay kits (Applied Biosystems), according to 
manufacturer’s protocols. Data were normalized with 18S expression, quantitatively 
analyzed by quantification cycles (Cq) and fold changes and graphically represented 
in amplification plots. MIQE guidelines were followed. 
 
In vivo Experiments and Tumor Size Determination 
Myoblasts and tumor cells were cultured as described above, mixed with a collagen 
carrier (1mg/ml) and bilaterally injected into the dorsal subcutaneous space of 8 
nude-mice (n=16 samples) per group. Cell-cell interactions in vivo were examined on 
day 21 and 42 after injection using nine groups: Myoblast (5x106) alone and co-
injected with each of the four cancer cell lines (LNCaP, PC3, DU145 and SK-LMS, 
2.5x106) and the four tumors alone (2.5x106). 
The experiments were performed in triplicates and repeated four times with 
myoblasts from 4 different patients. Tumor volume and growth was measured 
(mm3=a2xb/2). Animals were sacrificed by CO2 asphyxiation. Tumor/sample size, 
myoblast differentiation, tumor aggressiveness and metastasis (lymph node, lung and 
liver) were assessed after 21 and 42 days by histological staining.  
 
Histological Staining and Immunocytochemistry 
Cells/tissues were fixed (4% PFA), permeabilized (0,5% Triton), blocked (5% 
BSA/0,1% Triton) and immunolabelled with anti-Pax7 (1:200,Sigma), anti-MyoD 
(1:100,BDPharmingen), anti-Desmin (1:50,BDBiosciences), anti-MyH (1:4,DSHB) 
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and anti-sarcomeric actinin (1:1000,Sigma), and incubated for 1 hour with anti-
mouse-IgG-Cy3 (Sigma). Digital images were taken with a Leica Imager M1 
Microscope. Tissues were also stained with hematoxylin and eosin (HE). 
Histomorphometric analysis was performed using “IMAGEJ for microscopy”. 
 
Statistics 
Presented data are expressed as averages with corresponding standard deviation. 
Analyses by independent samples t-tests, one way ANOVA with Bonferroni post 
hoc analysis or Pearson Correlation were done with SPSS v20 (SPSS 
Inc,Chicago,IL). A p<0.05 was considered significant. 
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RESULTS 
Cancer cells undergo cell cycle arrest and apoptosis in co-culture with myoblasts in 
vitro 
Human myoblasts were successfully isolated and characterized by FACS, 
Immunocytochemistry (ICC) and Fiber Formation Assay (FFA). The cell population 
expressed 76.5 ± 2.3% PAX-7, 60.6 ± 6.3% MyOD, and 81.6 ± 2.5% desmin.  
After 10 days in co-culture cancer cell lines significantly decreased (p<0.001) their 
growth by 87.9±0.3% for DU145, 66.0±0.1% for LNCaP, 33.6±6.7% for PC3, and 
42.0±0.6% for SK-LMS1 (Figure 1A, 1B, 1C). The decrease in cancer cell growth was 
due to apoptosis and cell cycle arrest, as demonstrated by RT-qPCR and Western 
Blot (Figure 1D). LNCaP and PC3 showed a >9 fold increase of mRNA for Caspase 3 
and p21WAF when grown in co-culture, while DU145 and SK-LMS showed a lower but 
still significant increase. Western Blot confirmed these data. 
Myoblasts in co-culture with cancer cells (Figure 1E, 1F) displayed a decreased 
growth rate as well (Figure 1G), they fused and developed muscle fibers (Figure 1H, 
p<0.001). While only 4.2 ±1.0% of the control myoblasts formed muscle fibers, the 
differentiation ratio of myoblasts increased in parallel to the respective prostate 
cancer line aggressiveness (p=0.011), with rates of 11.5 ±5.5% in LNCaP, 14.5 
±6.9% in PC3 and 25.3 ±2.3% in DU145.  
 
TNFα-dependent induction of cell cycle arrest and apoptosis in cancer cell lines co-
cultured with myoblasts. 
Myoblasts demonstrated a striking, up to 25 fold, increase of TNFα mRNA when 
exposed to tumor (Figure 2A). This led to significantly higher amounts of TNFα 
protein (p<0.001) in the medium in the co-culture system (Figure 2B). The relative 
protein expression levels measured in the culture medium were 0.92±0.13 for 
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myoblast control and 3.01±0.17 for LNCaP, 4.71±0.26 for PC3, 5.88±0.26 for 
DU145 and 5.15±0.33 for SK-LMS co-cultures. These myoblast-TNFα-secretion 
values increased gradually according to the corresponding prostate carcinoma 
aggressiveness (p<0.001), significantly correlating (Pearson:0.754, p<0.001) with the 
myoblast differentiation ratio (Figure 2C). The TNFα concentration in culture 
medium also negatively correlated to cancer cell growth (p<0.001, Pearson 
value -0.58) suggesting that myoblast-paracrine-TNFα is sufficient to induce 
significant cancer growth inhibition. A parallel assay demonstrated that cancer 
cell lines alone do not reach detectable levels of TNFα mRNA or protein 
expression. 
TNFα-antibody blocking in co-culture permitted cancer re-growth at day 10 to 
84.0±0.3% for LNCaP, 99.1±11.4% for PC3, 23.3±0.3% for DU145 and 82.2±1.4% 
for SK-LMS1 (Figure 2D) of control values (=100%). Using TNFα blocking in co-
culture also decreased the myoblast differentiation ratio by reducing Caspase3 and 
p21WAF mRNA and protein expression to control-levels (Figure 2E).  
 
Myoblasts restrain tumor growth inducing cancer apoptosis and cell cycle arrest in 
vivo 
Interactions between myoblasts and prostate cancer were further investigated in vivo 
by co-injecting myoblasts and tumor cells subcutaneously in nude-mice (Figure 3A). 
All co-injected samples showed a significantly reduced tumor growth after 21 and 42 
days (Figure 3A, 3B. p<0.05). Despite rigorous mixing before injection, muscle and 
cancer grew in distinct clusters of each cell type (Figure 4). Immunohistochemistry 
was able to confirm the higher level of Caspase 3 and p21WAF expression in all co-
injected cancer samples. 
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Lymph node micrometastases (Figure 3C, 3D) were significantly reduced in co-
injected groups (10.9%), when compared to control (90.6%, p<0.001). No 
metastases to lung and liver were detected. The extent to which myoblasts 
influenced cancer growth was again proportional to cancer aggressiveness (Figure 
4). Histomorphometric distance analyses demonstrated that the tumor areas closer to 
the newly formed muscle underwent apoptosis and cell cycle arrest more intensely 
(Pearson: -0.91 and -0.86 respectively) supporting the hypothesis that soluble factors 
are responsible for the antitumor effects (Figure 5). Despite the evident changes in 
tumor behavior, muscle tissue developed a well-organized and differentiated 
structure in vivo. We could not detect any changes in muscle phenotype in the 
presence of tumor, which also preserved a similar expression of Desmin and p21WAF. 
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DISCUSSION 
Cell-cell interactions play a crucial role in tissue formation, regeneration processes 
and inflammatory reactions. Cellular signaling between neighboring cells is based on 
two main mechanisms: Growth modulation by endogenous secretion of active 
compounds and cell competition. These two mechanisms have been well 
documented in fibroblasts, which are capable of secreting growth factors and other 
peptides, thus delivering cues to neighboring cells. Fibroblasts isolated from breast 
tumor areas are permissive allowing breast cancer metastasis, whereas fibroblasts 
from normal breast tissue restrict tumor growth 14. Cell competition has also been 
proposed to regulate early cancer stages, when developing cancer cells overcome 
genomic constraints15. It triggers apoptosis within and around tumors by promoting 
rivalry between different anaplastic and normal cell lineages 15.  
We have demonstrated that myoblasts in co-culture with cancer cells significantly 
increase TNFα-secretion in vitro and in vivo. TNFα has been isolated and described 
30 years ago, and its clinical application in cancer therapy has been studied ever 
since 16. Due to its systemic toxicity, TNFα is clinically only recommended in the 
treatment of advanced neoplasia, including sarcoma and melanoma, and in 
advanced cases, when limb amputation would represent the next step17. Myoblasts 
are known to secrete higher TNFα levels when differentiating 18 and this paracrine-
secretion evokes microenvironmental changes, which control muscle regeneration by 
activating Pax7 in quiescent myoblasts and thereby induce differentiation and muscle 
formation 11.  
In our study myoblast-secreted-TNFα levels increase according to tumor 
aggressiveness, in accordance with previous findings correlating prostate cancer 
Gleason-score and inflammatory response to endogenous cytokines 19. The 
presence of inflammatory factors related to muscle regeneration plays a role in 
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myoblast-secreted-TNFα regulation 11. This leads to the hypothesis that specific 
inflammatory cues delivered by the prostate tumor stimulate neighboring myoblasts 
to produce higher TNFα levels. A potential pathway is the increase of TACE 
production due to stress and nutrient shortage, leading to increased release of 
endogenous TNFα by muscle cells 20.  
To investigate the paracrine influences we used a co-culture system where myoblast 
and cancer cells share the same environment without cell-cell-contact. All cancer cell 
lines in co-culture showed a significant decrease in growth and increase in apoptosis 
and cell cycle arrest. This inhibitory effect was almost completely blocked when 
TNFα was antagonized. In cancer cells TNFα binds to TNFR-1 receptor and triggers 
Caspase-3 activation leading to an apoptotic cascade and cell death 16. The dual 
effect of TNFα inducing differentiation in myoblasts and apoptosis in tumors can be 
explained by two parallel pathways: activation of p38α and c-Jun N-terminal kinase 
(JNK). Once p38α is activated, Pax7 initiates myogenesis and myoblast 
differentiation 11 and, by activating the JNK pathway, triggers cancer apoptosis 
through a Caspase-3-dependent pathway 12. A further line of action of TNFα in 
cancer inhibition affects tumor vascularity, probably due to higher response to TNFα 
in tumoral vessels by receptor up-regulation (TNFR-1) 16.  
Our findings demonstrate that co-injected myoblasts are able to limit cancer growth 
in vivo, again significantly triggering a cell cycle arrest and apoptosis in the cancer 
tissue. The histomorphometric distance analysis confirmed the role of a soluble factor 
in hindering tumor growth, supporting that TNFα might be a key player. Further, a 
significant reduction of lymph node metastasis formation was shown after co-
injection, indicating an effect on confining the cancer to the primary site. We 
anticipate that investigations targeting cancer-mediated-stress factors on muscle 
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cells as well as the additional effects of physical cell‐cell and cell‐ECM 
(extracellular matrix) interactions will be the focus of future efforts towards a 
better understanding of interactions between cancer and Adult Stem Cells, such as 
myoblasts.  
This research was based on established models for cancer research, however the 
complex interactions between stromal and tumor cells were not addressed. We used 
human myoblasts and cancer cell lines in an animal model. In order to avoid xenograft 
rejection nude mice with limited immune response were used.  
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CONCLUSIONS 
Myoblasts can be isolated from patients’ muscle biopsies, rapidly grown in culture, 
implanted and thereafter form functional muscle within weeks. Our results indicate 
that differentiating myoblasts secrete TNFα, which induces apoptosis and cell cycle 
arrest in prostate cancer. These characteristics make myoblasts a promising cell 
source for muscle reconstruction, even in the proximity of cancer.
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FIGURE LEGENDS 
 
 
Figure 1 – Co-culture effects on myoblasts and cancer cells. Cell growth rate, 
differentiation ratio, morphology and gene expression were influenced by co-culture. 
Prostate carcinoma and sarcoma cells significantly decreased in growth (A, B, E) and 
underwent apoptosis and/or cell cycle arrest (B, G). Activation of the apoptotic 
pathway was determined by staining for cleaved Caspase-3 (Asp175). A 
positive staining was found in DU145 cells in co-culture with myoblasts (A) but 
not in control of tumor alone (B). Desmin staining in co-culture (C) and control (D) 
demonstrated an evident differentiation of myoblasts into well-organized myotubes. 
Cytoskeleton labelled in green (Phalloidin 488) and secondary antibody in red (Cy3). 
Caspase 3 and p21 mRNA fold increase and protein expression (G) significantly 
increased when compared to tumor control (dashed line=1.0). Myoblasts 
differentiated rapidly in the presence of tumor, significantly increasing differentiation 
ratio and, consequently, decreasing cell growth (F, H). Samples in co-culture with 
myoblast were represented as (+ Mb) and control without myoblasts as (- Mb). 
mRNA fold increase was normalized with 18S reference gene (*p<0.05, **p<0.001). 
 
Figure 2 – Myoblast secreted TNFα induce myoblast differentiation and inhibit 
cancer cell line growth rate by inducing apoptosis and cell cycle arrest. (A) RT-
qPCR assay demonstrates that myoblast TNFα mRNA expression is increased after 
4 days of co-culture with different cancer cell lines. A significant difference could be 
found between different prostate cancer cell lines, increasing according to tumor 
aggressiveness. (B) Myoblasts TNFα secretion increases according to the cancer 
aggressiveness in co-culture. CM: Culture Medium. (C) Myoblast differentiation ratio 
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correlate (Pearson correlation: 0.754) to the amount of produced TNFα . (D) Cell 
growth rate of cancer (LNCaP, PC3, DU145 and SK-LMS-1) was assessed by cell 
counting at day 1, 4, 7 and 10 of co-culture. All cancer cell lines showed a significant 
decrease in growth in the presence of myoblasts (bold lines), when compared to 
control (fine line). Cancer growth rate was in great part recovered (dashed lines) after 
TNFα neutralization. (E) Apoptosis and cell cycle arrest are triggered in all cancer 
cells co-cultured with myoblasts. Again TNFα blocking reversed in great part these 
effects. Caspase 3 and p21 tumor control mRNA fold increase is represented with a 
dashed line (=1.0). *p<0.05, **p<0.001 
 
Figure 3 – Tumor growth and lymph node metastasis was reduced in vivo in 
samples co-injected with myoblasts. (A) 21 days after subcutaneous cell injection, 
tumor size was measured and a significant tumor size difference was found between 
co-injected and control samples. On day 42, myoblast co-injected tumor mass 
shrank, whereas control samples kept growing. (B) Final tumor size at day 42 was 
significantly smaller in myoblast co-injected samples. (C) Axillar lymph node 
metastasis assessment was performed by analysis of metastasis with H&E, Desmin 
and cytokeratin staining, positive lymph nodes. Ln ratio of axillar metastasis was also 
significantly reduced (p<0.001) in all tested cancers, when co-injected with 
myoblasts. (D) Pan-cytokeratin staining of mice axillar lymph node 3 weeks after 
subcutaneous injection of LNCaP with and without myoblasts. Samples co-
injected with myoblasts were represented as (+ Mb) and control without myoblasts as 
(- Mb). *p<0.05, **p<0.001 
 
Figure 4 – Histological analysis of tumor formation in vivo. At day 42, HE staining 
demonstrates a tendency of newly formed muscle and cancer tissue (first row) to 
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growth in clusters, with differentiated muscle areas impairing growth of neighbor 
tumor masses. In opposition, control cancers (second row) grow freely forming bigger 
and complex tumor masses. Increasing Caspase3 and p21WAF expression was 
detected in all tumors in samples co-injected with myoblasts (third and fifth row). Co-
injected myoblasts differentiated into p21 WAF positive muscle fibers. Samples co-
injected with myoblasts were represented as (+ Mb) and controls are cancer cell lines 
injected without myoblasts (-Mb). In the co-injected samples muscle is represented 
with a “M” and cancer tissue areas with a “C”. DAPI (blue), anti-mouse IgG Cy3 (red), 
and the injected myoblasts were labeled in vitro with PKH 67 (green).  
 
Figure 5 – Histomorphometric analyses of co-injected tumor with myoblasts. 
Histomorphometric analysis demonstrates a significant increase on apoptosis (A) and 
cell cycle arrest (B) in all co-injected tumors. (C) Three tumor areas were analyzed 
according to distance of newly formed muscle. The total positive area, calculated by 
fluorescence intensity, demonstrated a gradient of Caspase 3 and p21 expression in 
all cancers tested. These directly correlated with the proximity to differentiating 
muscle tissue. Samples co-injected with myoblast were represented as (+ Mb) and 
control without myoblasts as (- Mb). *p<0.05, **p<0.001 
 
 
Key of Definitions for Abbreviations 
 
TNFα – Tumor Necrosis Factor alpha 
FACS – Fluorescence-activated cell sorting 
WB – Western Blot 
RT-qPCR – real time quantitative polymerase chain reaction 
SUI – stress urinary incontinence 
VEGF – vascular endothelial growth factor 
NF-κB – nuclear-factor-κB 
JNK – c-Jun N-terminal kinase 
FBS – fetal bovine serum 
FFA - Fiber Formation Assay 
HPF – high-power-fields 
PFA – Paraformaldehyde 
HE – Hematoxylin and eosin 
ICC – Immunocytochemistry 
p21WAF – Cyclin-dependent kinase inhibitor 1A 
TNFR-1 – Tumor Necrosis Factor receptor 1 
Pax7 – Paired box protein 7 
MyoD – Myogenic Differentiation 
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